Editorial on the Research TopicThe Use of Chemotherapy in Treating Gastric Cancers Despite a declining trend in incidence globally, gastric cancer (GC) ranks 5 th in incidence and 4 th in mortality among 36 cancers across 185 countries. In 2020, over 1,089,000 new cases of GC and approximately 769,000 GC-associated new deaths were estimated worldwide (1-4). A noticeable proportion of GC cases are diagnosed at later stages, which can rule out resection as a primary treatment option, leaving systemic options which commonly involve chemotherapy, either as monotherapy or combined with other therapies (5-8). Chemotherapy is also frequently utilized in the adjuvant and/ or neoadjuvant setting for cases manageable with resection (9-11). Notably, chemotherapy may be prone to causing adverse effects in places beyond the malignant sites (12). This Research Topic, which has collected six high-quality original researches, aimed to highlight some of the novel emerging advancements pertaining to chemotherapy for GC, as well as the ways that physician scientists help patients with GC receiving chemotherapy by streamlining the treatment, and by delivering the drugs via individualized routes.Adjuvant chemotherapy may need to be administered timely in patients with resected GC upon recovery of performance statuses (9); Chen et al. explored the risk factors and prognostic impacts of delayed (>60 days after resection) or omitted adjuvant chemotherapy, which may be unacceptable, in resected TNM stage II-III GC by retrospectively analyzing data of 1520 patients undergoing radial gastrectomy, and